RFI

MENU

    RFI

    Drop in a message and we will reach out to you

    Blog

    Variation – how to successfully update your dossier

    13 June 2022

    Have you been granted the Marketing Authorisation (MA) for your medicinal product? Are you about to release it into the market? That is for sure very positive information! Do you think it is over and from now on, nothing more has to be done? Unfortunately not. During your product’s life cycle you will surely deal […]

    Read more
    Borderline products: drug or device? Line of demarcation drawn by new MDCG guidance

    31 May 2022

    Medical device regulation 2017/745 (MDR) entered into full application on May 26, 2021, but still a lot of uncertainty is associated with its implementation. So far, over 70 guidance documents have been published to assist stakeholders in applying MDR. Recently, a new Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017/745 […]

    Read more
    Clinical Evaluation Report – grounds for clinical evaluation of medical devices

    25 May 2022

    Clinical Evaluation Report (CER) constitutes a significant part of technical documentation (TD) that summarizes and draws conclusions on the clinical evaluation of the medical device (MD). The analysis and critical appraisal of clinical and non-clinical data regarding the device in question aims to demonstrate that the MD achieves its intended purpose with acceptable risk for […]

    Read more
    Brexit – is it still a concern for MA Holders?

    17 May 2022

    Time is passing very fast, relentlessly, and while it may seem that Brexit happened only yesterday, it in fact has been a long time since the British voters passed the 2016 referendum and United Kingdom (UK) has formally left the European Union (EU). As a result, on 31 January 2020 UK became a third country […]

    Read more
    Cultivation of non-fibrous hemp legal in Poland!

    09 May 2022

    The changes in act on counteracting drug addiction came into effect. On April 6, 2022, the Sejm of the Republic of Poland announced acts amending the act on counteracting drug addiction [1], [2]. The changes concern, among the others, the following areas: The regulation enables the cultivation of non-fibrous hemp, carried out in research institutes […]

    Read more
    Variations Regulation and implementation guidelines for type IA variations

    20 April 2022

    Are you planning to amend your product dossier and wondering how you should do this? Note that any changes to the terms of a marketing authorisation (MA) for medicinal products authorised pursuant to EU legislation should be notified to relevant Authority (or Authorities) as a variation. Provisions concerning the examination of variations to the terms […]

    Read more
    New template for responses in DC procedures

    21 March 2022

    The CMDh has approved a new template for applicants to provide their responses during DC procedures The CMDh guidance document “Applicant’s Response document in Mutual Recognition and Decentralised Procedures for Marketing Authorisation Applications” has been updated to reflect the use of the new template. According to chapter “Presentation / content of the Response document” – […]

    Read more
    Preparing a medical part of registration dossier – how not to go mad?

    09 March 2022

    Introducing a medicinal product on the market is a challenge. All these tests, exhausting hours in the laboratory, demanding studies, and when finally the success is on the horizon, it comes a day to prepare medical part* of a dossier. So you open the most important book of medical writers “Notice to Applicants, volume 2B” […]

    Read more
    Periodic safety update report (PSUR) – essential facts that you should know

    16 February 2022

    What is a Periodic safety update report (PSUR)? Periodic safety update report (PSUR) is a pharmacovigilance document intended to provide a critical, comprehensive evaluation of the risk-benefit balance of a medicinal product. For the purposes of lifecycle benefit-risk management, it is crucial to continue evaluating the risks and benefits of a medicinal product in everyday practice and […]

    Read more
    Veterinary Medicinal Products Regulation (EU) 2019/6 of the European Parliament and of the Council

    28 January 2022

    On 28 January 2022, ‘Regulation (EU) 2019/6 of the European Parliament and of the Council, repealing Directive 2001/82/EU’, comes into force. It introduces rules for the authorisation, use and control of veterinary medicinal products. The definition of veterinary medicinal products As defined in Regulation 2019/6, veterinary medicinal products are every substance intended for animals and […]

    Read more
    The quality data of medicinal products in the registration dossier

    19 January 2022

    Module 3 is a part of the Common Technical Document (CTD) that contains all  the quality data needed to the registration of a human medicinal product. The CTD is a special documentation format used for the submission of registration information of medicinal products to regulatory authorities. In 2003, it became required for all medicinal product […]

    Read more
    Medical Device Regulation – Regulatory aspects

    23 November 2021

    You’ve probably heard that after years of discussion, the European Medical Devices Regulation has been reviewed and was adopted on May 2017. Therefore the safety, quality and performance of medical devices destined for the EU market are now subject to new, more rigorous regulations that have entered into force. New regulation on medical devices – key […]

    Read more